Champions Oncology adds in-house SPECT/CT imaging to radiopharmaceutical development platform

Champions Oncology expanded its radiopharmaceutical development platform with in-house SPECT/CT imaging to support longitudinal in vivo uptake quantification.

• New capability links imaging results with terminal biodistribution, efficacy readouts, and molecular data from clinically annotated patient-derived xenograft models.
• Platform expansion adds a Radium-224/Lead-212 generator and Terbium-161, broadening available alpha- and beta-emitting isotope options.
• Move consolidates radiolabeling, imaging, and preclinical study execution into a single U.S.-based workflow aimed at earlier candidate selection decisions.